目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Distribution channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Ankylosing Spondylitis Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis

Chapter 4. Ankylosing Spondylitis Market: Drug Class Business Analysis
4.1. Drug Class Market Share, 2024 & 2033
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
4.4. Non-Steroidal Anti-Inflammatory Drug (NSAID)
4.4.1. Non-Steroidal Anti-Inflammatory Drug (NSAID) Market, 2021 - 2033 (USD Million)
4.5. TNF Inhibitors
4.5.1. TNF Inhibitors Market, 2021 - 2033 (USD Million)
4.5.2. Humira
4.5.2.1. Humira Market, 2021 - 2033 (USD Million)
4.5.3. Simponi
4.5.3.1. Simponi Market, 2021 - 2033 (USD Million)
4.5.4. Remicade
4.5.4.1. Remicade Market, 2021 - 2033 (USD Million)
4.5.5. Enbrel
4.5.5.1. Enbrel Market, 2021 - 2033 (USD Million)
4.5.6. Cimzia
4.5.6.1. Cimzia Market, 2021 - 2033 (USD Million)
4.5.7. Other TNF Inhibitors
4.5.7.1. Other TNF Inhibitors Market, 2021 - 2033 (USD Million)
4.6. Other Drug Classes
4.6.1. Other Drug Classes Market, 2021 - 2033 (USD Million)

Chapter 5. Ankylosing Spondylitis Market: Distribution Channel Business Analysis
5.1. Distribution Channel Market Share, 2024 & 2033
5.2. Distribution Channel Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
5.4. Hospital Pharmacy
5.4.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)
5.5. Retail Pharmacy
5.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
5.6. Others
5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Ankylosing Spondylitis Market: Regional Estimates & Trend Analysis
6.1. Regional Market Share Analysis, 2024 & 2033
6.2. Regional Market Dashboard
6.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
6.4. North America
6.4.1. North America Ankylosing Spondylitis Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
6.4.2. U.S.
6.4.2.1. Key Country Dynamics
6.4.2.2. Target Disease Prevalence
6.4.2.3. Regulatory Framework
6.4.2.4. Reimbursement Framework
6.4.2.5. U.S. Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3. Canada
6.4.3.1. Key Country Dynamics
6.4.3.2. Target Disease Prevalence
6.4.3.3. Regulatory Framework
6.4.3.4. Reimbursement Framework
6.4.3.5. U.S. Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.4. Mexico
6.4.4.1. Key Country Dynamics
6.4.4.2. Target Disease Prevalence
6.4.4.3. Regulatory Framework
6.4.4.4. Reimbursement Framework
6.4.4.5. Mexico Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Europe
6.5.1. Europe Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.2. UK
6.5.2.1. Key Country Dynamics
6.5.2.2. Target Disease Prevalence
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Framework
6.5.2.5. UK Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.3. Germany
6.5.3.1. Key Country Dynamics
6.5.3.2. Target Disease Prevalence
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Framework
6.5.3.5. Germany Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.4. France
6.5.4.1. Key Country Dynamics
6.5.4.2. Target Disease Prevalence
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Framework
6.5.4.5. France Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.5. Italy
6.5.5.1. Key Country Dynamics
6.5.5.2. Target Disease Prevalence
6.5.5.3. Regulatory Framework
6.5.5.4. Reimbursement Framework
6.5.5.5. Italy Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.6. Spain
6.5.6.1. Key Country Dynamics
6.5.6.2. Target Disease Prevalence
6.5.6.3. Regulatory Framework
6.5.6.4. Reimbursement Framework
6.5.6.5. Spain Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.7. Denmark
6.5.7.1. Key Country Dynamics
6.5.7.2. Target Disease Prevalence
6.5.7.3. Regulatory Framework
6.5.7.4. Reimbursement Framework
6.5.7.5. Denmark Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.8. Sweden
6.5.8.1. Key Country Dynamics
6.5.8.2. Target Disease Prevalence
6.5.8.3. Regulatory Framework
6.5.8.4. Reimbursement Framework
6.5.8.5. Sweden Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.9. Norway
6.5.9.1. Key Country Dynamics
6.5.9.2. Target Disease Prevalence
6.5.9.3. Regulatory Framework
6.5.9.4. Reimbursement Framework
6.5.9.5. Norway Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Asia Pacific
6.6.1. Asia Pacific Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.2. Japan
6.6.2.1. Key Country Dynamics
6.6.2.2. Target Disease Prevalence
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Framework
6.6.2.5. Japan Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.3. China
6.6.3.1. Key Country Dynamics
6.6.3.2. Target Disease Prevalence
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Framework
6.6.3.5. China Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.4. India
6.6.4.1. Key Country Dynamics
6.6.4.2. Target Disease Prevalence
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Framework
6.6.4.5. India Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.5. Australia
6.6.5.1. Key Country Dynamics
6.6.5.2. Target Disease Prevalence
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Framework
6.6.5.5. Australia Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.6. South Korea
6.6.6.1. Key Country Dynamics
6.6.6.2. Target Disease Prevalence
6.6.6.3. Regulatory Framework
6.6.6.4. Reimbursement Framework
6.6.6.5. South Korea Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.7. Thailand
6.6.7.1. Key Country Dynamics
6.6.7.2. Target Disease Prevalence
6.6.7.3. Regulatory Framework
6.6.7.4. Reimbursement Framework
6.6.7.5. Thailand Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Latin America
6.7.1. Latin America Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.2. Brazil
6.7.2.1. Key Country Dynamics
6.7.2.2. Target Disease Prevalence
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Framework
6.7.2.5. Brazil Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.3. Argentina
6.7.3.1. Key Country Dynamics
6.7.3.2. Target Disease Prevalence
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Framework
6.7.3.5. Argentina Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. Middle East and Africa
6.8.1. Middle East and Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.2. South Africa
6.8.2.1. Key Country Dynamics
6.8.2.2. Target Disease Prevalence
6.8.2.3. Regulatory Framework
6.8.2.4. Reimbursement Framework
6.8.2.5. South Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.3. Saudi Arabia
6.8.3.1. Key Country Dynamics
6.8.3.2. Target Disease Prevalence
6.8.3.3. Regulatory Framework
6.8.3.4. Reimbursement Framework
6.8.3.5. Saudi Arabia Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.4. UAE
6.8.4.1. Key Country Dynamics
6.8.4.2. Target Disease Prevalence
6.8.4.3. Regulatory Framework
6.8.4.4. Reimbursement Framework
6.8.4.5. UAE Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8.5. Kuwait
6.8.5.1. Key Country Dynamics
6.8.5.2. Target Disease Prevalence
6.8.5.3. Regulatory Framework
6.8.5.4. Reimbursement Framework
6.8.5.5. Kuwait Ankylosing Spondylitis Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape
7.1. Participant Overview
7.2. Company Market Position Analysis
7.3. Company Categorization
7.4. Strategy Mapping
7.5. Company Profiles/Listing
7.5.1. AbbiVie, Inc.
7.5.1.1. Overview
7.5.1.2. Financial Performance
7.5.1.3. Product Benchmarking
7.5.1.4. Strategic Initiatives
7.5.2. Amgen, Inc.
7.5.2.1. Overview
7.5.2.2. Financial Performance
7.5.2.3. Product Benchmarking
7.5.2.4. Strategic Initiatives
7.5.3. Pfizer, Inc.
7.5.3.1. Overview
7.5.3.2. Financial Performance
7.5.3.3. Product Benchmarking
7.5.3.4. Strategic Initiatives
7.5.4. Johnson & Johnson, Inc.
7.5.4.1. Overview
7.5.4.2. Financial Performance
7.5.4.3. Product Benchmarking
7.5.4.4. Strategic Initiatives
7.5.5. Novartis AG
7.5.5.1. Overview
7.5.5.2. Financial Performance
7.5.5.3. Product Benchmarking
7.5.5.4. Strategic Initiatives
7.5.6. UCB, Inc.
7.5.6.1. Overview
7.5.6.2. Financial Performance
7.5.6.3. Product Benchmarking
7.5.6.4. Strategic Initiatives
7.5.7. Eli Lilly and Company
7.5.7.1. Overview
7.5.7.2. Financial Performance
7.5.7.3. Product Benchmarking
7.5.7.4. Strategic Initiatives
7.5.8. Merck & Co., Inc.
7.5.8.1. Overview
7.5.8.2. Financial Performance
7.5.8.3. Product Benchmarking
7.5.8.4. Strategic Initiatives
7.5.9. Zydus Lifescience Ltd.
7.5.9.1. Overview
7.5.9.2. Financial Performance
7.5.9.3. Product Benchmarking
7.5.9.4. Strategic Initiatives
7.5.10. Izana Bioscience
7.5.10.1. Overview
7.5.10.2. Financial Performance
7.5.10.3. Product Benchmarking
7.5.10.4. Strategic Initiatives

List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. Global ankylosing spondylitis market, by region, 2021 - 2033 (USD Million)
Table 4. Global ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 5. Global ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 6. North America ankylosing spondylitis market, by country, 2021 - 2033 (USD Million)
Table 7. North America ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 8. North America ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 9. U.S. ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 10. U.S. ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 11. Canada ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 12. Canada ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 13. Mexico ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 14. Mexico ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 15. Europe ankylosing spondylitis market, by country, 2021 - 2033 (USD Million)
Table 16. Europe ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 17. Europe ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 18. UK ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 19. UK ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 20. Germany ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 21. Germany ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 22. France ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 23. France ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 24. Italy ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 25. Italy ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 26. Spain ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 27. Spain ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 28. Norway ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 29. Norway ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 30. Denmark ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 31. Denmark ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 32. Sweden ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 33. Sweden ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 34. Asia Pacific ankylosing spondylitis market, by country, 2021 - 2033 (USD Million)
Table 35. Asia Pacific ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 36. Asia Pacific ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD
Table 37. Japan ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 38. Japan ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 39. China ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 40. China ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 41. India ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 42. India ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 43. Australia ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 44. Australia ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 45. South Korea ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 46. South Korea ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 47. Thailand ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 48. Thailand ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 49. Latin America ankylosing spondylitis market, by country, 2021 - 2033 (USD Million)
Table 50. Latin America ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 51. Latin America ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 52. Brazil ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 53. Brazil ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 54. Argentina ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 55. Argentina ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 56. Middle East & Africa Ankylosing spondylitis market, by country, 2021 - 2033 (USD Million)
Table 57. Middle East & Africa ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 58. Middle East & Africa ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 59. South Africa ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 60. South Africa ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 61. Saudi Arabia ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 62. Saudi Arabia ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 63. UAE ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 64. UAE ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)
Table 65. Kuwait ankylosing spondylitis market, by drug class, 2021 - 2033 (USD Million)
Table 66. Kuwait ankylosing spondylitis market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures
Fig. 1 Ankylosing spondylitis market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Therapeutic approach and drug class outlook (USD Million)
Fig. 10 Competitive landscape
Fig. 11 Ankylosing spondylitis market dynamics
Fig. 12 Ankylosing spondylitis market: Porter’s five forces analysis
Fig. 13 Ankylosing spondylitis market: PESTLE analysis
Fig. 14 Drug Class market, 2021 - 2033 (USD Million)
Fig. 15 Non-Steroidal Anti-Inflammatory Drug (NSAID) market, 2021 - 2033 (USD Million)
Fig. 16 TNF Inhibitors market, 2021 - 2033 (USD Million)
Fig. 17 Humira market, 2021 - 2033 (USD Million)
Fig. 18 Simponi market, 2021 - 2033 (USD Million)
Fig. 19 Remicade market, 2021 - 2033 (USD Million)
Fig. 20 Enbrel market, 2021 - 2033 (USD Million)
Fig. 21 Cimzia market, 2021 - 2033 (USD Million)
Fig. 22 Other TNF Inhibitors market, 2021 - 2033 (USD Million)
Fig. 23 Other Drug Classes market, 2021 - 2033 (USD Million)
Fig. 24 Distribution channel market, 2021 - 2033 (USD Million)
Fig. 25 Hospital Pharmacy market, 2021 - 2033 (USD Million)
Fig. 26 Retail Pharmacy market, 2021 - 2033 (USD Million)
Fig. 27 Others market, 2021 - 2033 (USD Million)
Fig. 28 Ankylosing spondylitis market revenue, by region
Fig. 29 Regional marketplace: Key takeaways
Fig. 30 North America ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 31 U.S. country dynamics
Fig. 32 U.S. ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 33 Canada country dynamics
Fig. 34 Canada ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 35 Mexico country dynamics
Fig. 36 Mexico ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 37 Europe ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 38 UK country dynamics
Fig. 39 UK ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 40 Germany country dynamics
Fig. 41 Germany ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 42 France country dynamics
Fig. 43 France ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 44 Italy country dynamics
Fig. 45 Italy ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 46 Spain country dynamics
Fig. 47 Spain ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 48 Norway country dynamics
Fig. 49 Norway ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 50 Sweden country dynamics
Fig. 51 Sweden ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 52 Denmark country dynamics
Fig. 53 Denmark ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 54 Asia Pacific ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 55 Japan country dynamics
Fig. 56 Japan ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 57 China country dynamics
Fig. 58 China ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 59 India country dynamics
Fig. 60 India ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 61 Australia country dynamics
Fig. 62 Australia ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 63 South Korea country dynamics
Fig. 64 South Korea ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 65 Thailand country dynamics
Fig. 66 Thailand ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 67 Latin America ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 68 Brazil country dynamics
Fig. 69 Brazil ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 70 Argentina country dynamics
Fig. 71 Argentina ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 72 MEA ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 73 South Africa country dynamics
Fig. 74 South Africa ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 75 Saudi Arabia country dynamics
Fig. 76 Saudi Arabia ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 77 UAE country dynamics
Fig. 78 UAE ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 79 Kuwait country dynamics
Fig. 80 Kuwait ankylosing spondylitis market, 2021 - 2033 (USD Million)
Fig. 81 Company categorization
Fig. 82 Company market position analysis
Fig. 83 Strategic framework